The Boehringer Mannheim (BM; Boehringer Mannheirn, Laval Quebec, Canada) assay for creatine kinase-MB (CK-MB) measures the residual catalytic activity of the creatine kinase-B subunit after immunoinhibition of the M subunit. During our evaluation of this assay for implementation on the Hitachi 917 analyser we observed a profound positive interference from haemolysis. While the effect of erythrocyte adenylate kinase is widely known to users of CK assays, we found that there was significant interference even when the haemolysis could not be visually detected. We investigated the extent of this interference in order to determine the suitability of haernolysed specimens for this assay.
The Boehringer Mannheim (BM; Boehringer Mannheirn, Laval Quebec, Canada) assay for creatine kinase-MB (CK-MB) measures the residual catalytic activity of the creatine kinase-B subunit after immunoinhibition of the M subunit. During our evaluation of this assay for implementation on the Hitachi 917 analyser we observed a profound positive interference from haemolysis. While the effect of erythrocyte adenylate kinase is widely known to users of CK assays, we found that there was significant interference even when the haemolysis could not be visually detected. We investigated the extent of this interference in order to determine the suitability of haernolysed specimens for this assay.
MATERIALS AND METHODS
Haemolysis interference was investigated using the guidelines suggested by Sonntag et al.I In this procedure, varying concentrations of haemolysate are added to a pool of serum. The assay is performed on a range of haemolysatetreated specimens and the results are compared to results obtained from the untreated pooled serum. Five millilitres of lithium heparinated blood was centrifuged at 2500 rpm for 15 min. An aliquot of cells was then washed three times with 10 volumes of 0·9% NaCI solution. After the final wash, the erythrocytes were disrupted by incubating for 15 min at 4"C in five volumes of distilled water. Cellular debris was removed from the lysate by centrifugation. Varying concentrations of haernolysate was then added to several serum pools. The dilution ratio was kept at a constant value of 10% with normal saline. The baseline control specimen was treated with one-tenth volume of normal saline without haernolysate.
Each specimen was then assayed in duplicate on the BM/Hitachi 917 analyser according to the manufacturer's protocols. The coefficient of variation for the assay is 5·0% and 2·5% at 22 and 52 U/L CK-MB, respectively. Haemoglobin in each specimen was estimated spectrophotometrically.
RESULTS AND DISCUSSION
When serum containing haemoglobin in a concentration range of 0·014-0·285 giL was studied, we observed that the CK-MB value in the pooled specimen rose from a basal value of 11-18 U/L, an increase of 64%. Serum specimens spiked with up to 5·7 giL haemoglobin showed an increase in activity up to 1960% from baseline (see Figure I) .
The BM CK-MB immunoinhibition procedure is based on the procedure of Wurzburg et al." Residual CK activity is measured after the addition of an antibody specific to M subunits. This residual activity is specific to the B subunit of CK-MB provided there is no haemolysis, nor mitochondrial, macro CK and CK-BB forms present. Haemolysis interference is due to the release of erythrocyte adenylate kinase into the serum. The manufacturer has added diadenosine pentaphosphate (\0 Jimol/L) and adenosine monophosphate (6'0 mmol/L) to inhibit adenylate kinase. From this study it appears that the inhibition is incomplete. This interference is more apparent when CK-MB activity in the specimen is low. The interference is also more apparent when compared with the total CK assay and therefore, a greater spurious increase in activity is detected. Sonntag] reported that haemoglobin can be usually detected in serum at around 0·5 giL. This is in agreement with an informal study conducted in our laboratory. We employ the BM CK-MB immunoinhibition assay as our STAT screening assay for CK-MB activity, and we are concerned with spuriously elevated results from even the slightest amount of haemolysis. We measure haemolysis on the Hitachi 917 using the The BM CK-MB screening assay is a rapid method for ruling out the presence of CK-MB. However, this method is very sensitive to the effects of adenylate kinase from erythrocytes. Spuriously elevated CK-MB results are obtained from haemolysed specimens even when the haemolysis cannot be visually detected. We recommend that users of this assay measure haemolysis on all specimens. pre-programmed index with primary wavelength measurement at 340 nm and secondary wavelength measurement at 700 nm. When the analyser detects any haemolysis, we do not report the result but instead request a new specimen.
